Donanemab and Alzheimer’s Treatment Benefits

A SECONDARY analysis of the TRAILBLAZER-ALZ 2 trial has revealed that reduced posttreatment amyloid burden following donanemab administration is strongly correlated with slower clinical decline, reinforcing the therapeutic promise of donanemab…